BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom's Macroglobulinemia
Decision highlights the promise of BGB-16673, an investigational and potentially first-in-class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies
Article content
SAN CARLOS, Calif. — BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to the Company's investigational Bruton's tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of patients with Waldenstrom's macroglobulinemia (WM) previously treated with a BTK inhibitor.
Article content
'This is the Company's first PRIME designation, marking a milestone for BeOne and providing early and enhanced interaction with the EMA as we advance BGB-16673,' said Julie Lepin, Senior Vice President, Chief Regulatory Affairs Officer at BeOne. 'PRIME allows us to align early with the EMA on key evidence requirements and potentially accelerate our path to marketing authorization of BGB-16673 for patients with relapsed or refractory Waldenstrom's macroglobulinemia.'
Article content
In addition to the PRIME designation, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on the EU Orphan Drug Designation (ODD) application for BGB-16673 in WM. A final decision is anticipated in the coming weeks. The U.S. Food and Drug Administration (FDA) also granted Fast Track Designation to BGB-16673 for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), and adult patients with R/R mantle cell lymphoma (MCL).
Article content
The EMA's CHMP granted PRIME designation to BGB-16673 based on data demonstrating its novel mechanism and anti-tumor activity in B-cell malignancies. The CHMP recognized the limited treatment options available for WM patients post-BTK inhibitor therapy and acknowledged the strong biological rationale and promising clinical data for BGB-16673 in this setting, thereby demonstrating the potential to address the unmet medical need.
Article content
The PRIME initiative, launched by the EMA in 2016, provides early, proactive, and enhanced regulatory support to developers of promising medicines. It is designed to optimize development plans and accelerate evaluation, helping innovative therapies reach patients with unmet medical needs faster.
Article content
About BGB-16673
Article content
BGB-16673 is an orally available Bruton's tyrosine kinase (BTK) targeting protein degrader from BeOne's chimeric degradation activation compound (CDAC) platform. BGB-16673 is designed to promote the degradation, or breakdown, of both wild-type and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease. BGB-16673 is the most advanced BTK protein degrader in the clinic, with an extensive global clinical development program.
Article content
About BeOne Medicines
Article content
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.
Article content
Forward-Looking Statement
Article content
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's advancement of, and anticipated clinical development, regulatory milestones and commercialization of BGB-16673; the potential of BGB-16673 to significantly address the unmet medical need; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Contact
Article content
Article content
Liza Heapes
Article content
Article content
+1 857-302-5663
Article content
Article content
ir@beonemed.com
Article content
Media Contact
Article content
Article content
Kyle Blankenship
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
25 minutes ago
- National Post
Cinelease Acquired by Zello to Power the Next Era of Global Film & TV Production
Strategic acquisition expands production infrastructure, strengthens industry relationships, and unlocks scale across North America Article content LOS ANGELES — Zello, a private investment platform focused on scaling exceptional businesses in the broader entertainment industry, announced today that it has acquired Cinelease, a market leader in lighting and grip rentals, from Herc Rentals (NYSE: HRI). The transaction marks a defining move in Zello's strategy to support the infrastructure behind content creation — and power the future of global film and television production. Article content For over 45 years, Cinelease has been a trusted name in production support— renowned for its reliability, deep industry relationships, and service-first mindset. Under Zello's ownership, the company will continue to be led by industry veterans Mark Lamberton, Chris Rogers, and Gannon Murphy. Built on core values of responsiveness, dependability, and drive, Cinelease offers a robust inventory of lighting and grip equipment and serves as the professional manager of studio facilities owned by leading real estate investors. With operations spanning every major production hub in the U.S. and Canada, Cinelease supports thousands of film, television, and commercial productions annually through its integrated studio and equipment offerings. Article content Cinelease will operate as a standalone, privately held company backed by Zello's experienced team. With decades of operational expertise across studio management, equipment logistics, and production infrastructure, Zello will support Cinelease in deepening its market presence while remaining aligned with the needs of filmmakers and crews. This transition positions the company for disciplined expansion and reinforces its commitment to delivering world-class lighting, grip, and studio solutions. Article content 'Cinelease is built on trust—and a team that studios, crews, and producers have relied on for decades,' said Louis Dargenzio, CEO of Zello. 'This acquisition is about honoring that legacy while leaning into the future. We believe in this team, we believe in this brand, and we believe in the entertainment industry. We're excited to drive innovation and growth for our studio and production partners.' Article content 'This marks an exciting new chapter for Cinelease,' said Mark Lamberton, President of Cinelease. 'We're a company built on service, relationships, and delivering when it counts—led by people with a deep understanding of what it takes to make it happen. Zello brings deep respect for our foundation and the operational scale to help us go even further for the entertainment community. Together, we'll keep raising the bar for production support across North America.' Article content Zello was advised by Proskauer Rose LLP as legal counsel, EY as accounting advisor, and American Discovery Capital as financial advisor. Financing for the transaction was provided by MidCap Financial, a leading middle-market lender owned and managed by Apollo Global Management. Herc was advised by Sidley Austin LLP on legal matters and Goldman Sachs on financial matters. MidCap Financial was advised by Paul Hastings LLP on legal matters. Article content Article content About Cinelease Article content Founded in 1977, Cinelease is one of the most trusted names in production support—recognized for its reliability, deep industry relationships, and unwavering commitment to service. With operations across every major production hub in the U.S. and Canada, Cinelease supplies lighting and grip rentals, expendables, and sound stages to thousands of film, television, and commercial productions each year. Article content Cinelease also serves as the professional manager of studio facilities owned by leading real estate investors, offering an integrated platform that combines best-in-class equipment and scalable studio solutions. Its foundation is built on responsiveness, dependability, and drive—delivered by a deeply experienced team with an average tenure of over a decade. Article content From humble beginnings as a mom-and-pop operation to its evolution as an industry leader, Cinelease has remained true to its service-first ethos. Its culture is rooted in loyalty, collaboration, and a passion for supporting storytellers at every stage of production. Article content Zello is a next-generation investment platform where capital, creativity, and operational excellence converge. With core focus areas in content, high-growth businesses, and infrastructure, Zello builds, owns, and scales companies that power industries—starting with entertainment and expanding beyond. Article content Through an integrated approach, Zello combines disciplined investment, physical assets, and seasoned operating talent to scale proven models and back bold ideas. The platform is purpose built to help exceptional teams unlock long-term value and build enduring businesses. Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content
Globe and Mail
an hour ago
- Globe and Mail
Why Arm Holdings Stock Sank by Over 15% This Week
Key Points The company's second-quarter results displeased many investors. They also inspired some analyst price target cuts. 10 stocks we like better than Arm Holdings › Arm Holdings (NASDAQ: ARM) felt something like an unwanted limb over the past few days, largely because of an earnings report that struck the wrong chord with more than a few investors. Several analyst price target cuts only highlighted this disappointment. Ultimately, according to data compiled by S&P Global Market Intelligence, the specialty tech company's shares plummeted by over 15% this week. Top-line growth, bottom-line slide U.K.-based Arm published its results for the first quarter of its fiscal 2026 on Wednesday. The report showed that the company managed to increase its total revenue by 12% year over year to slightly more than $1.05 billion. That was largely due to a 25% increase in royalty revenue, which landed at $585 million, and despite a 1% slump in licensing revenue to $468 million. Non- GAAP (adjusted) net income traveled in the opposite direction. It fell to $374 million, or $0.35 per share, compared with the year-ago profit of $419 million. With those numbers, Arm met the consensus analyst estimate for profitability, although it missed slightly on revenue -- pundits following the stock were expecting it to earn $1.06 billion. More of a concern for investors was management's guidance for the company's current (second) quarter. Its forecast is for $1.01 billion to $1.11 billion in revenue, which, if achieved, would be down or, at best, essentially flat over the first quarter. Meanwhile, adjusted earnings were forecast at $0.29 to $0.37. Bearish analyst moves Although analyst reactions to the quarter were mixed, enough pundits trimmed their price targets to affect sentiment on the stock. UBS 's Timothy Arcuri, for one, shaved his fair value assessment to $175 per Arm share from his preceding $185. He did, however, maintain his buy recommendation. Lee Simpson of Morgan Stanley acted similarly, reducing the price target to $180 per share from $194 while keeping an overweight (buy, in other words) rating intact. Should you invest $1,000 in Arm Holdings right now? Before you buy stock in Arm Holdings, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arm Holdings wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
CTV News
2 hours ago
- CTV News
CTV National News: U.S. added just 73,000 jobs in July
Watch U.S. President Donald Trump has ordered the firing of the head of the Bureau of Labor Statistics after job numbers were lower than expected in July.
